PUBLISHER: The Business Research Company | PRODUCT CODE: 1588823
PUBLISHER: The Business Research Company | PRODUCT CODE: 1588823
Digital dose inhalers (DDIs) are sophisticated inhalation devices that feature sensors and digital capabilities to monitor and track medication usage. They deliver precise doses of medication to the lungs, primarily for treating asthma and chronic obstructive pulmonary disease (COPD). DDIs also offer real-time data and reminders, which enhance medication adherence and disease management.
The main types of digital dose inhalers are metered dose inhalers (MDI) and dry powder inhalers (DPI). A metered dose inhaler (MDI) administers a specific amount of medication to the lungs in aerosol form. Medications can be branded or generic. DDIs are indicated for asthma, COPD, and other respiratory conditions. End users include the medical device industry and hospitals.
The digital dose inhalers market research report is one of a series of new reports from The Business Research Company that provides digital dose inhalers market statistics, including digital dose inhalers industry global market size, regional shares, competitors with a digital dose inhalers market share, detailed digital dose inhalers market segments, market trends and opportunities, and any further data you may need to thrive in the digital dose inhalers industry. This digital dose inhalers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The digital dose inhalers market size has grown exponentially in recent years. It will grow from $16.08 billion in 2023 to $19.60 billion in 2024 at a compound annual growth rate (CAGR) of 21.9%. The growth during the historic period can be attributed to the rise in respiratory diseases, the growing adoption of digital dose inhalers, the increasing need for precise dosing monitoring, a larger geriatric population, and a greater emphasis on personalized healthcare.
The digital dose inhalers market size is expected to see exponential growth in the next few years. It will grow to $43.38 billion in 2028 at a compound annual growth rate (CAGR) of 22.0%. The growth in the forecast period can be attributed to the expansion of telemedicine, the increasing prevalence of respiratory diseases, the growing need for better medication adherence and management, and rising consumer awareness. Key trends during this period include the integration of digital technologies, heightened consumer education and awareness, cost-effectiveness, incorporation of IoT and AI, and the continued growth of telemedicine.
The rising prevalence of chronic respiratory diseases is projected to drive growth in the digital dose inhalers market. Chronic respiratory diseases are long-term conditions affecting the lungs and airways, leading to persistent breathing difficulties. Contributing factors to the increasing prevalence include elevated air pollution levels, an aging population, and rising tobacco use. Digital dose inhalers are crucial for enhancing medication adherence and monitoring for patients with conditions such as asthma and chronic obstructive pulmonary disease (COPD). For example, in March 2022, the Centers for Disease Control and Prevention reported an increase in tuberculosis infections, with 7,860 cases in 2021 compared to 7,173 cases in 2020. This growing prevalence of chronic respiratory diseases is driving the expansion of the digital dose inhalers market.
Key companies in the digital dose inhalers market are concentrating on developing innovative products, such as smart inhalers, to improve patient outcomes and medication management. Smart inhalers are advanced devices equipped with sensors and connectivity features that monitor drug usage, inhalation techniques, and adherence, while providing real-time feedback through mobile applications. For instance, in June 2024, Aseptika Ltd., a UK-based healthcare company, introduced the PUFFClicker3 universal smart inhaler dose tracker at the Med-Tech Innovation Expo. The PUFFClicker3 is the first inhaler dose tracker compatible with both pressurized metered dose inhalers (pMDI) and dry powder inhalers (DPI), supporting 101 SNOMED-coded inhaler types. This innovation facilitates patient transitions between different inhaler types and includes built-in graphical instructions for using each supported inhaler.
In September 2021, Philip Morris International Inc., a US-based tobacco company, acquired Vectura Group for £1.1 billion ($1.37 billion). This acquisition is intended to diversify Philip Morris's business into inhaled over-the-counter and prescription drugs. Vectura Group Limited, based in the UK, is a provider of digital dose inhalers.
Major companies operating in the digital dose inhalers market are AstraZeneca plc, Novartis AG, 3M Company, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., C.H. Boehringer Sohn AG & Co. KG, AptarGroup Inc., Cipla Limited, Chiesi Farmaceutici S.p.A., Lupin Limited, Glenmark Pharmaceuticals Limited, OPKO Health Inc., Nemera, Sensirion AG, Sunovion Pharmaceuticals Inc., MannKind Corporation, Adherium Limited, H&T Presspart, Monaghan Medical Corporation, BreatheSuite Inc.
North America was the largest region in the digital dose inhalers market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital dose inhalers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the digital dose inhalers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The digital dose inhalers market consists of sales of nebulizers with digital features, digital dose-recording inhalers, and combination digital inhalers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Digital Dose Inhalers Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on digital dose inhalers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for digital dose inhalers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The digital dose inhalers market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of COVID-19 on supply chains and consumption patterns.